RANCHO CORDOVA, Calif.,
Sept 2, 2020 /PRNewswire/
-- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market
leader in automated cell processing tools and services in the cell
and gene therapy field, along with its joint venture, ImmuneCyte,
Inc. today announced plans to roll out a comprehensive diagnostic
and therapeutic product line to fight the global COVID-19 pandemic.
The multi-pronged strategy will combine diagnostic, therapeutic and
service offerings to better detect, track and fight the novel
coronavirus. Details regarding the strategy will be included in the
company's presentation at the LD Micro 500 Conference on
Wednesday, September 2 at
5 p.m. EST.
A live webcast of the presentation will be available on the
ThermoGenesis website at:
An archived replay will be available for a period of 90 days after
The spread of COVID-19, both domestically and internationally,
has led to a significant unmet need for rapid disease diagnosis,
systematic serological surveillance and improved therapeutics, to
precede and complement the introduction of vaccines. In response,
ThermoGenesis, along with its joint venture ImmuneCyte, is
developing a comprehensive list of RT-PCR and antigen test products
to complement its SARS-CoV-2 IgM/IgG Antibody Test Kit, which has
already been granted Emergency Use Authorization (EUA). The
joint venture also plans to offer full CLIA certified lab testing
services to its clients, making ThermoGenesis a one-stop shop for
all testing needs. Additionally, the ImmuneCyte joint venture is
actively developing a robust therapeutic pipeline to treat
"The comprehensive diagnostic and therapeutic product pipeline
we envisage for COVID-19 will facilitate ThermoGenesis' ability to
become a one-stop solution for our customers," stated Chris Xu, Ph.D, Chairman and Chief Executive
Officer of ThermoGenesis. "This multi-pronged approach, we believe,
will be critical to reopening the economy, tracking the virus, and
minimizing the loss of life as we continue to develop and expand
our product solutions for COVID-19."
About ThermoGenesis Holdings, Inc.
Holdings, Inc. develops, commercializes, and markets a range of
automated technologies for CAR-T and other cell-based therapies.
The Company currently markets a full suite of solutions for
automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology, including its semi-automated,
functionally-closed CAR-TXpress™ platform, which streamlines
the manufacturing process for the emerging CAR-T immunotherapy
market. For more information about ThermoGenesis, please
About ImmuneCyte, Inc.
ImmuneCyte, Inc., is a joint
venture which 19% owned by ThermoGenesis. The Company develops
various immunological products and services and provides clients
the opportunity to bank their own immune cells when the cells are
"healthy and unaffected" as a future resource for cellular
immunotherapies, such as CAR-T. ImmuneCyte utilizes a proprietary
CAR-TXpress™ platform, a GMP compliant close-system capable of
automated separating and cryopreserving different components from
blood, simultaneously. For more information about ImmuneCyte, Inc.,
please visit: www.immunecyte.com.
This press release contains
"forward-looking statements" within the meaning of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect the current expectations of ThermoGenesis concerning future
events and results. Forward-looking statements based on
ThermoGenesis' current assumptions, expectations and beliefs are
generally identifiable by use of words "may," "might," "will,"
"should," "expects," "plans," "anticipates," "believes,"
"estimates," "predicts," "potential" or "continue," or similar
expressions and involve significant risks and uncertainties that
could cause actual results, developments and business decisions to
differ materially from those contemplated by these statements. Such
forward-looking statements involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, market and other conditions, as well as those risk
factors discussed in Item 1A of our most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission ("SEC")
as well as other documents that may be filed by ThermoGenesis from
time to time with the SEC, which are available at www.sec.gov.
We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law. You are
cautioned not to unduly rely on such forward-looking statements
when evaluating the information presented in this press
Paula Schwartz, Rx
SOURCE ThermoGenesis Holdings, Inc.